LitCovid-sentences  

PMC:7195088 / 14447-34332 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T89 0-151 Sentence denotes Drug Class/mechanism Published RCT Ongoing RCT for treatment/prevention of COVID-19 (recruiting or not yet recruiting) registered at ClinicalTrials.gov
T90 152-218 Sentence denotes Lopinavir/ritonavir Lopinavir is an HIV type 1 protease inhibitor.
T91 219-411 Sentence denotes Ritonavir is a CYP3A4 inhibitor that boosts lopinavir concentrations • Open-label RCT comparing lopinavir/ritonavir (99 patients) vs. standard of care (100) in patients with COVID-19 in China.
T92 412-489 Sentence denotes Lopinavir/ritonavir was administered at the dosage of 400/100 mg for 14 days.
T93 490-569 Sentence denotes The primary time-to-event endpoint was clinical improvement from randomization.
T94 570-958 Sentence denotes In the primary study population (ITT), no statistically significant differences were observed with regard to the primary endpoint of clinical improvement (HR 1.24 with standard of care as reference, 95% CI 0.90 to 1.72) and the secondary endpoint of 28-day mortality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7).
T95 959-1112 Sentence denotes In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care.
T96 1113-1285 Sentence denotes Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19.
T97 1286-1327 Sentence denotes Open-label RCT (NCT04307693, recruiting).
T98 1328-1387 Sentence denotes Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.
T99 1388-1491 Sentence denotes • Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae.
T100 1492-1541 Sentence denotes Open-label RCT (NCT04261907, not yet recruiting).
T101 1542-1711 Sentence denotes Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).
T102 1712-1814 Sentence denotes • Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19.
T103 1815-1856 Sentence denotes Open-label RCT (NCT04252885, recruiting).
T104 1857-1933 Sentence denotes Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.
T105 1934-2059 Sentence denotes • Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19.
T106 2060-2101 Sentence denotes Open-label RCT (NCT04276688, recruiting).
T107 2102-2184 Sentence denotes Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).
T108 2185-2328 Sentence denotes • Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia.
T109 2329-2370 Sentence denotes Open-label RCT (NCT04255017, recruiting).
T110 2371-2646 Sentence denotes Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 > 93% or Pao 2/Fio 2 > 300 mm Hg); (b) time to lung recovery.
T111 2647-2759 Sentence denotes • Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19.
T112 2760-2811 Sentence denotes Double-blind RCT (NCT04328285, not yet recruiting).
T113 2812-2906 Sentence denotes Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).
T114 2907-3023 Sentence denotes • Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia.
T115 3024-3073 Sentence denotes Open-label RCT (NCT04286503, not yet recruiting).
T116 3074-3256 Sentence denotes Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.
T117 3257-3439 Sentence denotes • Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19.
T118 3440-3489 Sentence denotes Open-label RCT (NCT04295551, not yet recruiting).
T119 3490-3551 Sentence denotes Primary endpoint: clinical recovery time (follow-up 28 days).
T120 3552-3721 Sentence denotes • Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19.
T121 3722-3771 Sentence denotes Open-label RCT (NCT04275388, not yet recruiting).
T122 3772-3833 Sentence denotes Primary endpoint: clinical recovery time (follow-up 14 days).
T123 3834-4013 Sentence denotes • Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19.
T124 4014-4055 Sentence denotes Open-label RCT (NCT04251871, recruiting).
T125 4056-4133 Sentence denotes Primary endpoint: time to complete remission of symptoms (follow-up 28 days).
T126 4134-4349 Sentence denotes • Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia.
T127 4350-4403 Sentence denotes Partly blinded RCT (NCT04331470, not yet recruiting).
T128 4404-4485 Sentence denotes Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.
T129 4486-4597 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19.
T130 4598-4659 Sentence denotes Double-blind, adaptive RCT (NCT04328012, not yet recruiting).
T131 4660-4736 Sentence denotes Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).
T132 4737-4906 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19.
T133 4907-4960 Sentence denotes Double-blind, adaptive RCT (NCT04315948, recruiting).
T134 4961-5032 Sentence denotes Primary endpoint: severity rating on a 7-point ordinal scale at day 15.
T135 5033-5332 Sentence denotes • Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19.
T136 5333-5384 Sentence denotes Single-blind RCT (NCT04323345, not yet recruiting).
T137 5385-5578 Sentence denotes Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).
T138 5579-5716 Sentence denotes • Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19.
T139 5717-5766 Sentence denotes Open-label RCT (NCT04328480, not yet recruiting).
T140 5767-5825 Sentence denotes Primary endpoint: all-cause mortality (follow-up 30 days).
T141 5826-6230 Sentence denotes • Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19.
T142 6231-6280 Sentence denotes Open-label RCT (NCT04303299, not yet recruiting).
T143 6281-6348 Sentence denotes Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).
T144 6349-6379 Sentence denotes Remdesivir Adenosine analogue.
T145 6380-6545 Sentence denotes It binds to RNA-dependent RNA polymerase and acts as an RNA-chain terminator • Not available • Comparison of remdesivir vs. placebo in patients with severe COVID-19.
T146 6546-6589 Sentence denotes Double-blind RCT (NCT04257656, recruiting).
T147 6590-6679 Sentence denotes Primary endpoint: clinical status, assessed by an ordinal scale at days 7, 14, 21 and 28.
T148 6680-6762 Sentence denotes • Comparison of remdesivir vs. placebo in patients with mild to moderate COVID-19.
T149 6763-6806 Sentence denotes Double-blind RCT (NCT04252664, recruiting).
T150 6807-6880 Sentence denotes Primary endpoint: time to clinical recovery in hours (follow-up 28 days).
T151 6881-6968 Sentence denotes • Comparison of remdesivir vs. local standard of care in patients with severe COVID-19.
T152 6969-7010 Sentence denotes Open-label RCT (NCT04252664, recruiting).
T153 7011-7118 Sentence denotes Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days).
T154 7119-7208 Sentence denotes • Comparison of remdesivir vs. local standard of care in patients with moderate COVID-19.
T155 7209-7250 Sentence denotes Open-label RCT (NCT04292730, recruiting).
T156 7251-7297 Sentence denotes Primary endpoint: discharged status at day 14.
T157 7298-7363 Sentence denotes • Comparison of remdesivir vs. placebo in patients with COVID-19.
T158 7364-7407 Sentence denotes Double-blind RCT (NCT04280705, recruiting).
T159 7408-7479 Sentence denotes Primary endpoint: severity rating on a 8-point ordinal scale at day 15.
T160 7480-7595 Sentence denotes • Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19.
T161 7596-7654 Sentence denotes Open-label adaptive RCT (NCT04321616, not yet recruiting).
T162 7655-7725 Sentence denotes Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).
T163 7726-7895 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19.
T164 7896-7949 Sentence denotes Double-blind, adaptive RCT (NCT04315948, recruiting).
T165 7950-8021 Sentence denotes Primary endpoint: severity rating on a 7-point ordinal scale at day 15.
T166 8022-8089 Sentence denotes Darunavir/cobicistat Darunavir is an HIV type 1 protease inhibitor.
T167 8090-8270 Sentence denotes Cobicistat is a CYP3A4 inhibitor that boosts darunavir concentrations • Not available • Comparison of darunavir/cobicistat vs. standard of care in patients with COVID-19 pneumonia.
T168 8271-8312 Sentence denotes Open-label RCT (NCT04252274, recruiting).
T169 8313-8427 Sentence denotes Primary endpoint: virologic clearance rate of throat swabs, sputum or lower respiratory tract secretions at day 7.
T170 8428-8734 Sentence denotes Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir.
T171 8735-8910 Sentence denotes The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19.
T172 8911-8952 Sentence denotes Open-label RCT (NCT04310228, recruiting).
T173 8953-9006 Sentence denotes Primary endpoint: clinical cure (follow-up 3 months).
T174 9007-9411 Sentence denotes • Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19.
T175 9412-9461 Sentence denotes Open-label RCT (NCT04303299, not yet recruiting).
T176 9462-9529 Sentence denotes Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).
T177 9530-9638 Sentence denotes • Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19.
T178 9639-9680 Sentence denotes Open-label RCT (NCT04304053, recruiting).
T179 9681-9798 Sentence denotes Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days).
T180 9799-9898 Sentence denotes • Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19.
T181 9899-9942 Sentence denotes Double-blind RCT (NCT04319900, recruiting).
T182 9943-10114 Sentence denotes Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days).
T183 10115-10190 Sentence denotes • Comparison of favipiravir vs. standard of care in patients with COVID-19.
T184 10191-10240 Sentence denotes Open-label RCT (NCT04333589, not yet recruiting).
T185 10241-10353 Sentence denotes Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months).
T186 10354-10758 Sentence denotes • Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19.
T187 10759-10808 Sentence denotes Open-label RCT (NCT04303299, not yet recruiting).
T188 10809-10876 Sentence denotes Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).
T189 10877-11169 Sentence denotes Umifenovir Anti-influenza membrane fusion inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir.
T190 11170-11326 Sentence denotes The manuscript is publicly available but still to be peer reviewed [30] • Comparison of umifenovir vs. standard of care in patients with COVID-19 pneumonia.
T191 11327-11376 Sentence denotes Open-label RCT (NCT04260594, not yet recruiting).
T192 11377-11445 Sentence denotes Primary endpoint: virus negative conversion rate (follow-up 7 days).
T193 11446-11825 Sentence denotes Chloroquine, hydroxychloroquine Some proposed mechanisms are the following: increase in the endosomal Ph necessary for the virus/host cell fusion; interference with the glycosylation of cell receptors; immunomodulatory activity • Not available • Comparison of different hydroxychloroquine dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare workers a risk).
T194 11826-11950 Sentence denotes Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting).
T195 11951-12148 Sentence denotes Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months).
T196 12149-12235 Sentence denotes • Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients.
T197 12236-12287 Sentence denotes Double-blind RCT (NCT04328961, not yet recruiting).
T198 12288-12356 Sentence denotes Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days).
T199 12357-12493 Sentence denotes • Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19.
T200 12494-12543 Sentence denotes Open-label RCT (NCT04332094, not yet recruiting).
T201 12544-12771 Sentence denotes Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19.
T202 12772-12821 Sentence denotes Open-label RCT (NCT04330586, not yet recruiting).
T203 12822-12895 Sentence denotes Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14.
T204 12896-13022 Sentence denotes • Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors.
T205 13023-13074 Sentence denotes Double-blind RCT (NCT04330495, not yet recruiting).
T206 13075-13285 Sentence denotes Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).
T207 13286-13394 Sentence denotes • Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk.
T208 13395-13446 Sentence denotes Double-blind RCT (NCT04328467, not yet recruiting).
T209 13447-13509 Sentence denotes Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks).
T210 13510-13622 Sentence denotes • Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19.
T211 13623-13674 Sentence denotes Double-blind RCT (NCT04328285, not yet recruiting).
T212 13675-13692 Sentence denotes Primary endpoint:
T213 13693-13781 Sentence denotes Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).
T214 13782-13903 Sentence denotes • Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households.
T215 13904-13947 Sentence denotes Double-blind RCT (NCT04308668, recruiting).
T216 13948-14095 Sentence denotes Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14.
T217 14096-14211 Sentence denotes • Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19.
T218 14212-14270 Sentence denotes Open-label adaptive RCT (NCT04321616, not yet recruiting).
T219 14271-14341 Sentence denotes Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).
T220 14342-14453 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19.
T221 14454-14515 Sentence denotes Double-blind, adaptive RCT (NCT04328012, not yet recruiting).
T222 14516-14592 Sentence denotes Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days).
T223 14593-14751 Sentence denotes • Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19.
T224 14752-14801 Sentence denotes Open-label RCT (NCT04332835, not yet recruiting).
T225 14802-14981 Sentence denotes Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28.
T226 14982-15151 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19.
T227 15152-15205 Sentence denotes Double-blind, adaptive RCT (NCT04315948, recruiting).
T228 15206-15277 Sentence denotes Primary endpoint: severity rating on a 7-point ordinal scale at day 15.
T229 15278-15640 Sentence denotes Methylprednisolone A subgroup of patients with severe COVID-19 might develop a cytokine storm syndrome which causes rapidly progressive pneumonia, ARDS and clinical deterioration and corticosteroids administration may halt the dysregulated cytokine release • Not available • Comparison of methylprednisolone vs. standard of care in patients with severe COVID-19.
T230 15641-15682 Sentence denotes Open-label RCT (NCT04244591, recruiting).
T231 15683-15749 Sentence denotes Primary endpoint: lower Murray lung injury score at days 7 and 14.
T232 15750-15832 Sentence denotes • Comparison of methylprednisolone vs. standard of care in patients with COVID-19.
T233 15833-15874 Sentence denotes Open-label RCT (NCT04273321, recruiting).
T234 15875-15931 Sentence denotes Primary endpoint: treatment failure (follow-up 14 days).
T235 15932-16132 Sentence denotes • Comparison of inhaled alpha interferon plus methylprednisolone plus umifenovir vs. thalidomide plus inhaled alpha interferon plus methylprednisolone plus umifenovir in patients with severe COVID-19.
T236 16133-16184 Sentence denotes Double-blind RCT (NCT04273581, not yet recruiting).
T237 16185-16252 Sentence denotes Primary endpoint: time to clinical improvement (follow-up 28 days).
T238 16253-16335 Sentence denotes • Comparison of different dosages of methylprednisolone in patients with COVID-19.
T239 16336-16377 Sentence denotes Open-label RCT (NCT04263402, recruiting).
T240 16378-16459 Sentence denotes Primary endpoints: (a) disease readmission at day 7; (b) critical stage at day 7.
T241 16460-16568 Sentence denotes • Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19.
T242 16569-16618 Sentence denotes Open-label RCT (NCT04329650, not yet recruiting).
T243 16619-16670 Sentence denotes Primary endpoint: ICU admission (follow-up 29 days)
T244 16671-16787 Sentence denotes Tocilizumab Humanized monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors.
T245 16788-17038 Sentence denotes IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytokine release that has been observed in severe COVID-19 • Not available • Comparison of tocilizumab vs. standard of care in patients with COVID-19.
T246 17039-17088 Sentence denotes Open-label RCT (NCT04331808, not yet recruiting).
T247 17089-17191 Sentence denotes Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).
T248 17192-17295 Sentence denotes • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19.
T249 17296-17337 Sentence denotes Open-label RCT (NCT04310228, recruiting).
T250 17338-17391 Sentence denotes Primary endpoint: clinical cure (follow-up 3 months).
T251 17392-17471 Sentence denotes • Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19.
T252 17472-17523 Sentence denotes Double-blind RCT (NCT04320615, not yet recruiting).
T253 17524-17595 Sentence denotes Primary endpoint: severity rating on a 7-point ordinal scale at day 28.
T254 17596-17732 Sentence denotes • Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19.
T255 17733-17782 Sentence denotes Open-label RCT (NCT04332094, not yet recruiting).
T256 17783-17916 Sentence denotes Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).
T257 17917-18072 Sentence denotes • Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19.
T258 18073-18122 Sentence denotes Open-label RCT (NCT04333914, not yet recruiting).
T259 18123-18140 Sentence denotes Primary endpoint:
T260 18141-18157 Sentence denotes 28-day survival.
T261 18158-18359 Sentence denotes • Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19.
T262 18360-18409 Sentence denotes Open-label RCT (NCT04322773, not yet recruiting).
T263 18410-18503 Sentence denotes Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).
T264 18504-18705 Sentence denotes • Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19.
T265 18706-18755 Sentence denotes Open-label RCT (NCT04330638, not yet recruiting).
T266 18756-18823 Sentence denotes Primary endpoint: time to clinical improvement (follow-up 15 days).
T267 18824-18940 Sentence denotes • Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia.
T268 18941-18990 Sentence denotes Open-label RCT (NCT04286503, not yet recruiting).
T269 18991-19173 Sentence denotes Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.
T270 19174-19211 Sentence denotes Anakinra Antagonist of IL-1 receptor.
T271 19212-19468 Sentence denotes IL-1 is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome. • Not available • Comparison of anakinra vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of care in patients with COVID-19.
T272 19469-19518 Sentence denotes Open-label RCT (NCT04324021, not yet recruiting).
T273 19519-19565 Sentence denotes Primary endpoint: treatment success at day 15.
T274 19566-19767 Sentence denotes • Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19.
T275 19768-19817 Sentence denotes Open-label RCT (NCT04330638, not yet recruiting).
T276 19818-19885 Sentence denotes Primary endpoint: time to clinical improvement (follow-up 15 days).